Insider Selling: DexCom, Inc. (NASDAQ:DXCM) EVP Sells 3,116 Shares of Stock

DexCom, Inc. (NASDAQ:DXCM) EVP Steven Robert Pacelli sold 3,116 shares of the business’s stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $149.65, for a total value of $466,309.40. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Steven Robert Pacelli also recently made the following trade(s):

  • On Thursday, May 23rd, Steven Robert Pacelli sold 3,597 shares of DexCom stock. The shares were sold at an average price of $116.71, for a total value of $419,805.87.
  • On Tuesday, April 23rd, Steven Robert Pacelli sold 3,596 shares of DexCom stock. The shares were sold at an average price of $116.61, for a total value of $419,329.56.

NASDAQ DXCM traded up $5.82 during trading hours on Thursday, reaching $153.39. The company’s stock had a trading volume of 903,066 shares, compared to its average volume of 1,268,832. The business’s 50-day moving average is $141.68. The company has a quick ratio of 6.75, a current ratio of 7.18 and a debt-to-equity ratio of 1.57. DexCom, Inc. has a 1 year low of $92.33 and a 1 year high of $157.50. The stock has a market cap of $13.40 billion, a P/E ratio of 511.30 and a beta of 0.82.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Wednesday, May 1st. The medical device company reported ($0.05) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.17) by $0.12. DexCom had a positive return on equity of 8.45% and a negative net margin of 11.51%. The company had revenue of $280.50 million for the quarter, compared to the consensus estimate of $246.10 million. During the same quarter in the prior year, the company posted ($0.30) EPS. DexCom’s quarterly revenue was up 52.1% on a year-over-year basis. Sell-side analysts anticipate that DexCom, Inc. will post 0.81 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Prudential Financial Inc. increased its holdings in shares of DexCom by 2.2% in the fourth quarter. Prudential Financial Inc. now owns 4,668 shares of the medical device company’s stock valued at $559,000 after purchasing an additional 100 shares during the period. OLD National Bancorp IN grew its holdings in DexCom by 1.1% in the second quarter. OLD National Bancorp IN now owns 9,838 shares of the medical device company’s stock valued at $1,474,000 after purchasing an additional 108 shares during the period. Nisa Investment Advisors LLC lifted its position in shares of DexCom by 4.4% in the second quarter. Nisa Investment Advisors LLC now owns 2,750 shares of the medical device company’s stock valued at $412,000 after acquiring an additional 115 shares in the last quarter. Alps Advisors Inc. lifted its position in shares of DexCom by 3.6% in the first quarter. Alps Advisors Inc. now owns 3,659 shares of the medical device company’s stock valued at $436,000 after acquiring an additional 126 shares in the last quarter. Finally, Raymond James Financial Services Advisors Inc. lifted its position in shares of DexCom by 1.6% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 8,293 shares of the medical device company’s stock valued at $994,000 after acquiring an additional 131 shares in the last quarter. 96.40% of the stock is currently owned by institutional investors and hedge funds.

DXCM has been the subject of a number of recent research reports. Zacks Investment Research downgraded GALP ENERGIA SG/ADR from a “hold” rating to a “sell” rating in a research note on Monday, May 6th. UBS Group lifted their price objective on Spotify Technology from $180.00 to $182.00 and gave the company a “buy” rating in a research report on Tuesday, April 30th. BidaskClub cut Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, June 26th. Northland Securities reaffirmed a “hold” rating and set a $125.00 price objective on shares of DexCom in a research report on Thursday, June 6th. Finally, TheStreet cut The Providence Service from a “b-” rating to a “c+” rating in a research report on Friday, June 28th. Five analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $150.65.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

See Also: Buy-Side Analysts

Insider Buying and Selling by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.